Zhimeng Biopharma
Discovering and developing the most effective, safe and affordable drugs to improve the quality of life of patients in China and abroad.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 Valuation: €0.0 | round | |
* | CNY350m | Series B | |
| Total Funding | 000k | ||
Related Content
Zhimeng Biopharma, founded in 2017 and based in Shanghai's Zhangjiang High Tech Park, is a biotech startup focused on developing medicines for chronic hepatitis B (CHB) and related liver diseases. The company aims to discover and develop the most effective, safe, and affordable drugs to improve the quality of life for patients both in China and globally. Zhimeng employs a comprehensive strategy to combat CHB by targeting the hepatitis B virus (HBV) with multiple approaches and restoring the host immune systems. The company serves patients suffering from chronic hepatitis B and other liver diseases, operating primarily in the pharmaceutical and biotech markets. Zhimeng's business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and sale of these drugs, as well as potential partnerships and licensing agreements. The company is also involved in early clinical development programs for drug candidates targeting neurological conditions such as epilepsy, pain, depression, and stroke.
Keywords: chronic hepatitis B, liver diseases, biotech, pharmaceutical, innovative therapies, HBV, immune restoration, clinical trials, neurology, Shanghai.